DEA Acting Administrator Timothy Shea Delivers Remarks at the Operation DisrupTor Press Conference Department of Justice, Washington, D.C. September 22, 2020

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

While the presence of fentanyl powder (lethal in doses as small as two milligrams) poses a public safety threat, the ingestion of fentanyl via vaping poses a threat of unknown consequences to the user and those nearby.

Statement by DEA Acting Administrator Timothy Shea - Operation Crystal Shield Press Conference - Phoenix,Arizona September 10, 2020

The Drug Enforcement Administration (DEA) Heroin Signature Program (HSP) analyzes hundreds of wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...

The Drug Enforcement Administration’s (DEA) Philadelphia Field Division (PFD) Intelligence Program conducted an analysis of drug availability and abuse for the State of Delaware. This product highlights significant findings regarding various drug trends since last reported in 2017. The primary drug threats identified in Delaware are illicit opioids, cocaine, controlled...

The HSP (Heroin Signature Program) is one essential component of the DEA’s Intelligence Program to identify trends in heroin trafficking and distribution in the United States. The objective of the program is to identify and quantify the chemical components of heroin seized at U.S. ports of entry (POE), all non-POE...

Since 2009, Drug Enforcement Administration (DEA) reporting from the Los Angeles Field Division (LAFD) has explored drug-related mortality in the LAFD area of responsibility (AOR), which includes the State of Nevada. In 2019, LAFD personnel reviewed post-mortem toxicology records from the period between 2015 and 2018. These records show that...

DEA's Philadelphia Division conducted a review of laboratory analyzed drug seizures for Pennsylvania. The results of analyzing this data formed the basis for estimating the level of drugs present in Pennsylvania and highlights trends in drug availability.